Tags

Type your tag names separated by a space and hit enter

Recent advances in the treatment of rhinovirus infections.
Curr Opin Pharmacol. 2001 Oct; 1(5):477-81.CO

Abstract

Rhinoviruses are the most common causes of viral respiratory infections and complications caused by viral respiratory infections in patients with underlying lung disease. Major recent therapeutic advances include the development of capsid-function inhibitors (pleconaril), inhibitors of 3C protease (AG7088), and recombinant soluble intercellular adhesion molecule (sICAM)-1, all of which exhibit potent antirhinoviral activity in vitro and varying activity in clinical trials. Pleconaril and AG7088 have shown the most promise and are the most advanced in clinical trials.

Authors+Show Affiliations

ViroPharma Incorporated, Exton, Pennsylvania 19341, USA. mmckinlay@viropharma.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11764773

Citation

McKinlay, M A.. "Recent Advances in the Treatment of Rhinovirus Infections." Current Opinion in Pharmacology, vol. 1, no. 5, 2001, pp. 477-81.
McKinlay MA. Recent advances in the treatment of rhinovirus infections. Curr Opin Pharmacol. 2001;1(5):477-81.
McKinlay, M. A. (2001). Recent advances in the treatment of rhinovirus infections. Current Opinion in Pharmacology, 1(5), 477-81.
McKinlay MA. Recent Advances in the Treatment of Rhinovirus Infections. Curr Opin Pharmacol. 2001;1(5):477-81. PubMed PMID: 11764773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent advances in the treatment of rhinovirus infections. A1 - McKinlay,M A, PY - 2002/1/5/pubmed PY - 2002/5/15/medline PY - 2002/1/5/entrez SP - 477 EP - 81 JF - Current opinion in pharmacology JO - Curr Opin Pharmacol VL - 1 IS - 5 N2 - Rhinoviruses are the most common causes of viral respiratory infections and complications caused by viral respiratory infections in patients with underlying lung disease. Major recent therapeutic advances include the development of capsid-function inhibitors (pleconaril), inhibitors of 3C protease (AG7088), and recombinant soluble intercellular adhesion molecule (sICAM)-1, all of which exhibit potent antirhinoviral activity in vitro and varying activity in clinical trials. Pleconaril and AG7088 have shown the most promise and are the most advanced in clinical trials. SN - 1471-4892 UR - https://www.unboundmedicine.com/medline/citation/11764773/Recent_advances_in_the_treatment_of_rhinovirus_infections_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1471-4892(01)00083-2 DB - PRIME DP - Unbound Medicine ER -